Key facts
- Strados Labs’s last known valuation is $37.5M (Jan 2026).
- It has raised $21.1M across 4 recorded rounds; the latest was Seed Round ($3.1M) in Jul 2021.
- Notable investors include US National Science Foundation, MassChallenge, SOSV, MedTech Innovator, HAX — 31 tracked in total.
- Strados Labs has filed 5 Form Ds with the SEC since 2019, most recently Jun 2022 ($585K sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 31 names
- ·Watchlist + deal alerts for Strados Labs
Funding rounds
4 roundsAbout Strados Labs
Developer of a medical device designed to transform respiratory disease management with continuous lung sound monitoring. The company's device is connected with a continuous breathing sensor that collects respiratory data, for data analysis, enabling doctors to connect with asthma and chronic obstructive pulmonary disease patients and to monitor their respiratory status, including frequency of coughs, wheezes, as well as the duration of inhalation and exhalation remotely.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2016
- Employees
- 48
- Website
- stradoslabs.com/
- Ownership
- Privately Held (backing)
Strados Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Strados Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Strados Labs in its N-PORT filings yet. We sweep new filings monthly.